Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While GHRP-2 is used in research to induce robust GH pulses and study anabolic and metabolic effects; clinically developed as pralmorelin for GH deficiency diagnostics6272, Liraglutide is approved for type 2 diabetes and weight management, improving glycemic control and inducing weight loss through GLP-1–mediated insulinotropic, glucagonostatic, and appetite-suppressing actions6880.
While GHRP-2 works as a second-generation hexapeptide growth hormone–releasing peptide that mimics ghrelin by agonizing GHSR-1a, strongly stimulating pulsatile GH release and modestly raising prolactin, ACTH, and cortisol62723096, Liraglutide is a human GLP-1 analog with a single amino-acid substitution (Lys34→Arg) and a C16 palmitoyl fatty acid attached to Lys26 via a glutamate linker, producing a long-acting GLP-1 receptor agonist6880.
GHRP-2
GHSR
Liraglutide
GCG
Both peptides fall into a similar broad context as Hormone peptides, although the details of how they are used and discussed still diverge. Both are often discussed in Metabolic and endocrine contexts, while GHRP-2 is more of a hormone peptide and Liraglutide is better described as a metabolic peptide. Both appear to work through Receptor agonist, but the functional emphasis still separates, with GHRP-2 leaning toward Anabolic growth and Liraglutide leaning toward Metabolic regulation. GHRP-2 has a more synthetic design origin, while Liraglutide is closer to synthetic analog background and their development context also differs, with GHRP-2 in Clinical phase 1 while Liraglutide is approved. GHRP-2 takes the form of a linear peptide, whereas Liraglutide is closer to a peptide conjugate, GHRP-2 carries d-amino acid substitution and amidation features, while Liraglutide instead reflects palmitoylation changes; while their sequence patterns also diverge, with GHRP-2 showing protein-mimetic sequence features and Liraglutide showing alpha-helical domain features.